OPC-21268
new
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529801

CAS#: 131631-89-5

Description: OPC-21268 is a vasopressin 1 receptor antagonist potentially for the treatment of heart failure and hypertension.


Price and Availability

Size Price Shipping out time Quantity
25mg USD 150 Same Day
50mg USD 250 Same Day
100mg USD 450 Same Day
200mg USD 750 Same Day
500mg USD 1550 Same Day
1g USD 2650 Same Day
2g USD 4250 Same Day
5g USD 6950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-28. Prices are subject to change without notice.

OPC-21268, purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 529801
Name: OPC-21268
CAS#: 131631-89-5
Chemical Formula: C26H31N3O4
Exact Mass: 449.23
Molecular Weight: 449.55
Elemental Analysis: C, 69.47; H, 6.95; N, 9.35; O, 14.24


Synonym: OPC-21268; OPC21268; OPC 21268

IUPAC/Chemical Name: N-(3-(4-(4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidine-1-carbonyl)phenoxy)propyl)acetamide

InChi Key: KSNUCNRMDYJBKT-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H31N3O4/c1-19(30)27-15-4-18-33-23-10-7-21(8-11-23)26(32)28-16-13-22(14-17-28)29-24-6-3-2-5-20(24)9-12-25(29)31/h2-3,5-8,10-11,22H,4,9,12-18H2,1H3,(H,27,30)

SMILES Code: CC(NCCCOC1=CC=C(C(N2CCC(N3C(CCC4=C3C=CC=C4)=O)CC2)=O)C=C1)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Shinoura H, Take H, Itoh S, Hirasawa A, Inoue K, Ohno Y, Hashimoto K, Tsujimoto G. Key amino acids of vasopressin V1a receptor responsible for the species difference in the affinity of OPC-21268. FEBS Lett. 2000 Jan 28;466(2-3):255-8. Erratum in: FEBS Lett 2000 Jun 2;474(2-3):257. PubMed PMID: 10682838.

2: Sugimoto I, Narimiya N, Odagiri M, Ohnishi A, Tanaka T. Protective effect of a vasopressin-1 selective antagonist, OPC-21268, against ethanol-induced damage of the rat gastric wall. Dig Dis Sci. 1999 Mar;44(3):503-9. PubMed PMID: 10080141.

3: Bemana I, Nagao S. Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats. Neurosurgery. 1999 Jan;44(1):148-54; discussion 154-5. PubMed PMID: 9894975.

4: Kawano Y, Matsuoka H, Nishikimi T, Takishita S, Omae T. The role of vasopressin in essential hypertension. Plasma levels and effects of the V1 receptor antagonist OPC-21268 during different dietary sodium intakes. Am J Hypertens. 1997 Nov;10(11):1240-4. PubMed PMID: 9397242.

5: Otsuka F, Ogura T, Yamauchi T, Oishi T, Hashimoto M, Mimura Y, Makino H. Effects of OPC-21268, a vasopressin V1-receptor antagonist, on expression of growth factors from glomeruli in spontaneously hypertensive rats. Regul Pept. 1997 Oct 31;72(2-3):87-95. PubMed PMID: 9652981.

6: Bemana I, Takahashi E, Nakamura T, Kuyama H, Nagao S. OPC-21268, an orally effective, nonpeptide arginine vasopressin V1 receptor antagonist reduces vasogenic brain edema. Acta Neurochir Suppl. 1997;70:194-7. PubMed PMID: 9416320.

7: Mimura Y, Ogura T, Hayakawa N, Otsuka F, Hashimoto M, Yamauchi T, Makino H, Ogawa N. In vitro macro- and microautoradiographic localization of V1 and V2 receptors in the rat kidney using OPC-21268 and OPC-31260. Nephron. 1997;76(3):331-6. PubMed PMID: 9226235.

8: Kurihara I, Saito T, Obara K, Shoji Y, Hirai M, Soma J, Sato H, Imai Y, Abe K. Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis. Nephron. 1996;73(4):629-36. PubMed PMID: 8856262.

9: Kato K, Kannan H, Ohta H, Kemuriyama T, Maruyama S, Tandai-Hiruma M, Sato Y, Nakazato M, Nishimori T, Ishida Y, Onaka T, Nishida Y. Central endogenous vasopressin induced by central salt-loading participates in body fluid homeostasis through modulatory effects on neurones of the paraventricular nucleus in conscious rats. J Neuroendocrinol. 2009 Nov;21(11):921-34. doi: 10.1111/j.1365-2826.2009.01915.x. PubMed PMID: 19732288.

10: Chihara T, Nakamura S, Onogawa T, Yamashita T, Yamamura Y, Mori T, Tominaga M, Yabuuchi Y. OPC-21268 antagonizes arginine vasopressin-induced vasoconstrictor response in the spinally-anesthetized dog. Jpn J Pharmacol. 1995 Jul;68(3):345-7. PubMed PMID: 7474558.

11: Atke A, Vilhardt H, Hauzerova L, Barth T, Andersen LF. Effects of the non-peptide inhibitor OPC-21268 on oxytocin and vasopressin stimulation of rat and human myometrium. Eur J Pharmacol. 1995 Jul 25;281(1):63-8. PubMed PMID: 8566118.

12: Naitoh M, Suzuki H, Murakami M, Matsumoto A, Arakawa K, Ichihara A, Nakamoto H, Oka K, Yamamura Y, Saruta T. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 1994 Dec;267(6 Pt 2):H2245-54. PubMed PMID: 7810724.

13: Shinouraa2 H, Takea2 H, Itohb S, Hirasawaa A, Inouec K, Ohnoc Y, Hashimotod K, Tsujimotoa G. Corrigendum to: key amino acids of vasopressin V1a receptor responsible for the species difference in the affinity of OPC-21268 (FEBS 23227). FEBS Lett. 2000 Jun 2;474(2-3):257. PubMed PMID: 10838096.

14: Maejima S, Yamada T, Hamada T, Matsuda K, Uchiyama M. Effects of hypertonic stimuli and arginine vasotocin (AVT) on water absorption response in Japanese treefrog, Hyla japonica. Gen Comp Endocrinol. 2008 Jun;157(2):196-202. doi: 10.1016/j.ygcen.2008.04.014. PubMed PMID: 18555070.

15: Yamada Y, Yamamura Y, Chihara T, Onogawa T, Nakamura S, Yamashita T, Mori T, Tominaga M, Yabuuchi Y. OPC-21268, a vasopressin V1 antagonist, produces hypotension in spontaneously hypertensive rats. Hypertension. 1994 Feb;23(2):200-4. PubMed PMID: 8307629.

16: Li X, Kribben A, Wieder ED, Tsai P, Nemenoff RA, Schrier RW. Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268. Hypertension. 1994 Feb;23(2):217-22. PubMed PMID: 8307632.

17: Burrell LM, Phillips PA, Stephenson J, Risvanis J, Hutchins AM, Johnston CI. Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat. J Endocrinol. 1993 Aug;138(2):259-66. PubMed PMID: 8228734.

18: Jamil KM, Watanabe T, Nakao A, Okuda T, Kurokawa K. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells. Biochem Biophys Res Commun. 1993 Jun 15;193(2):738-43. PubMed PMID: 8390252.

19: Masaki H, Imaizumi T, Harada S, Momohara M, Hirooka Y, Takeshita A. Effects of a novel orally effective V1-receptor antagonist, OPC-21268, on AVP-induced sympathoinhibition. Am J Physiol. 1993 Jun;264(6 Pt 2):R1089-94. PubMed PMID: 8391757.

20: Nakamura T, Sakamaki T, Kurashina T, Hoshino J, Sato K, Ono Z, Murata K. Effect of vasopressin V (OPC-21268) and V2 (OPC-31260) antagonists on renal hemodynamics and excretory function. Life Sci. 1994;55(4):PL67-72. PubMed PMID: 8028441.